← FDA DRUG APPROVALS

FDA ANDA · ANDA090545

NAPROXEN SODIUM 220MG

Sponsor: MARKSANS PHARMA

APPLICATION
ANDA090545
TYPE
ANDA
ORIGINAL APPROVAL
2011-03-16
LATEST ACTION
2023-07-21
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Over-the-counter

Products

NAPROXEN SODIUMOver-the-counter
NAPROXEN SODIUM 220MG · TABLET · ORAL

Approval history

2023-07-21Labeling · Supplement 1 · standardAP
2023-07-21Labeling · Supplement 4 · standardAP
2023-07-21Labeling · Supplement 2 · standardAP
2011-03-16OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →